Tag - CFRX

Markets

Analysts downgrade ContraFect after DSMB urges Phase 3 MRSA trial end

Analysts for SVB Securities and Maxim Group downgraded ContraFect (NASDAQ:CFRX) after a data safety monitoring board recommended termination for futility of a Phase 3 trial evaluating exebacase in methicillin-resistant...

July 14, 2022

Markets

SVB Leerink starts ContraFect at OP; PT $14

SVB Leerink initiated coverage of ContraFect (NASDAQ:CFRX) with an “outperform” rating and sum-of-the-parts price target of $14. The stock closed at $3.90 on Sept. 8. Analyst Roanna Ruiz, Ph.D., writes that...

September 9, 2021

Tag - CFRX

Analysts downgrade ContraFect after DSMB urges Phase 3 MRSA trial end

SVB Leerink starts ContraFect at OP; PT $14

General

More